Open AccessPartial Response to Pyrotinib Plus Capecitabine in an Advanced Breast Cancer Patient with HER2 Amplification and R157W Mutation After Anti-HER2 Treatment: A Case Report and Literature Review
Author(s) -
Ying Qu,
Yufeng Liu,
Kailin Ding,
Yong Li,
Xiaoyu Hong,
Haibo Zhang
Publication year - 2021
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s289876
Subject(s) - capecitabine , medicine , breast cancer , oncology , mutation , cancer , bioinformatics , genetics , biology , gene , colorectal cancer
Human epidermal growth factor receptor2 ( HER2 ) overexpression/amplification is associated with high malignancy, rapid disease progression and poor overall survival in breast cancer. The application of anti- HER2 drugs has greatly improved the survival of patients with HER2 -positive breast cancer, but drug resistance issues affect the long-term efficacy. The HER2 mutation is considered to be one of the reasons for resistance to anti- HER2 therapy, and there is currently no standard treatment. We report for the first time the detection of HER2 amplification with R157W mutation by second-generation sequencing (NGS) in a 57-year-old hormone receptor-negative, HER2 -positive woman with advanced breast cancer who was resistant to multi-line anti- HER2 therapies. She subsequently received pyrotinib combined with capecitabine treatment and achieved partial response. The small-molecule pan- HER family irreversible inhibitor pyrotinib combined with capecitabine has shown a promising effect in the treatment of HER2 mutation-induced resistance, but the molecular mechanism and efficacy need to be further verified.